{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-008210","form_type":"8-K","ticker":null,"cik":"0001621227","company_name":"Adaptimmune Therapeutics PLC","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.287266+00:00","generated_at":"2026-06-01T23:11:02.655107+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adaptimmune Q1 net loss $48.5M; afami-cel PDUFA Aug 4; secures $125M debt","bullets":["Revenue $5.7M (down from $47.6M YoY); net loss $48.5M vs profit $1.0M in Q1 2023.","FDA PDUFA date for afami-cel BLA set for August 4, 2024; GMP and GCP inspections ongoing.","Secured up to $125M debt financing with Hercules Capital; first $25M available at close.","Lete-cel pivotal trial IGNYTE-ESO met primary efficacy endpoint; full analysis expected late 2024.","Cash and cash equivalents $140.7M; cash runway extended into late 2025 with anticipated afami-cel revenues."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-008210","json":"https://secwatch.observer/filing/0001558370-24-008210.json","markdown":"https://secwatch.observer/filing/0001558370-24-008210.md","text":"https://secwatch.observer/filing/0001558370-24-008210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024008210/0001558370-24-008210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024008210/adap-20240515x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:11:02.655107+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"76dc49229e05c0fe649d5cb533ab06aeabeee784","claim":"Adaptimmune Therapeutics PLC reported first quarter ended March 31, 2024 results: revenue $5.7 million.","evidence_excerpt":"Revenue for the three months ended March 31, 2024, was $5.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1621227/000155837024008210/0001558370-24-008210-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$5.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}